Peptide LocalCompare price, evidence & access
Search /Compare vendors
Regions/Global status checker
One name + one destination

Peptide status
by country.

Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.

Identity+Destination=Verification route
41tracked names
42country guides
3separate evidence lanes
99official source routes
Global source router

Two selections. No category shortcuts.

Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.

Status check updated to Liraglutide in België. Product-specific FDA and EU medicine records.

Current source route

Liraglutide in België

Open exact country guide
Direct answer / België

Can you buy Liraglutide in België?

Product-specific FDA and EU medicine records

SAXENDA is a product-specific liraglutide prescription medicine authorized in the United States and European Union for defined populations and uses. Those authorizations do not transfer to every liraglutide product, compounded preparation, imported pen, indication, presentation, online seller, or supply route, and they do not establish current launch, reimbursement, availability, or authorization outside those records.

  1. 01
    Resolve the nameFDA-approved medicine
  2. 02
    Check BelgiëFDA-approved medicine
  3. 03
    Verify the exact offerProduct, seller, and supply route must match
Identity recordProduct-specific FDA and EU medicine records

What Liraglutide resolves to

SAXENDA is a product-specific liraglutide prescription medicine authorized in the United States and European Union for defined populations and uses. Those authorizations do not transfer to every liraglutide product, compounded preparation, imported pen, indication, presentation, online seller, or supply route, and they do not establish current launch, reimbursement, availability, or authorization outside those records.

Evidence lane
FDA-approved medicine
Current record
NDA 206321 · FDA-approved prescription drug
Checked
July 17, 2026
liraglutideSaxendaNN2211NDA 206321GLP-1 receptor agonist
Destination recordFAGG-product- en apotheekcontrole vereist

What België still has to prove

Een Nederlandstalige gids voor zoekopdrachten naar peptiden, peptidegeneesmiddelen, middelen voor gewichtsbeheersing en onderzoeksmaterialen in België. Zoek eerst het exacte geneesmiddel in de databank van het FAGG en controleer daarna de openbare apotheek en haar website via de officiële internetapotheekroute, zonder taal, europrijs of Belgische bezorging als bewijs te behandelen.

Comparison mode
EUR / FAGG-geneesmiddelen- en internetapotheekrecords
Price coverage
Geen gekwalificeerde Belgische verkoperstabel
Guide updated
18 juli 2026
Product recordDatabank van geneesmiddelen met geldige vergunningenFederaal Agentschap voor Geneesmiddelen en Gezondheidsproducten ↗Seller or supply recordOfficiële route voor internetapothekenFederaal Agentschap voor Geneesmiddelen en Gezondheidsproducten ↗
Evidence coverageRouting records only

No compound-specific official record is attached to this exact pairing yet. That is an evidence gap, not proof of approval, prohibition, availability, or absence. Use the country guide and official product and seller routes to verify the exact offer.

Open the full country check
Result boundaryIdentity match ≠ destination approval ≠ verified seller

This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.

Popular starting points

Open a common peptide and country check.

Each selection has a shareable URL, so you can send someone the exact peptide and destination without losing the identity or country context.

01CagriSema in South AfricaInvestigational clinical program02CagriSema in PortugalInvestigational clinical program03Retatrutide in ArgentinaInvestigational clinical program04Melanotan II in ItaliaUS research-market identity05PT-141 / Bremelanotide in ItaliaUS research-market identity with a separate FDA-approved medicine record06CJC-1295 DAC in FranceUS research-market identity07BPC-157 in FranceUS research-market identity08BPC-157 in DeutschlandUS research-market identity09Retatrutide in MéxicoInvestigational clinical program10Mazdutide in 中国China-approved medicine and active clinical program11Ecnoglutide in 中国China-approved medicine and active development program12Enicepatide in FranceInvestigational clinical program13Eloralintide in DeutschlandInvestigational clinical program14Tirzepatide in CanadaUS FDA medicine reference15Cagrilintide in United KingdomInvestigational clinical program16Petrelintide in DeutschlandInvestigational clinical program17MariTide in AustraliaInvestigational clinical program18Survodutide in FranceInvestigational clinical program19VK2735 in United StatesInvestigational clinical program20Pemvidutide in United StatesInvestigational clinical program21Semaglutide in الإمارات العربية المتحدةProduct-specific approved medicine records in multiple jurisdictions22Semaglutide in FranceProduct-specific approved medicine records in multiple jurisdictions23Semaglutide in CanadaProduct-specific approved medicine records in multiple jurisdictions24TB-500 in United StatesUS research-market identity25TB-500 in CanadaUS research-market identity26GHK-Cu in CanadaUS research-market identity27Semax in South AfricaUS research-market identity28Melanotan II in AustraliaUS research-market identity29MOTS-c in CanadaUS research-market identity30Tesamorelin in United StatesUS research-market identity with a separate FDA-licensed medicine record31AOD-9604 in South AfricaUS research-market identity with a failed oral obesity program and no FDA-approved drug32Ipamorelin in CanadaUS research-market identity33Selank in South AfricaUS research-market identity34PT-141 / Bremelanotide in United StatesUS research-market identity with a separate FDA-approved medicine record35CJC-1295 no DAC in CanadaUS research-market identity36CJC-1295 DAC in South AfricaUS research-market identity
Direct answers

What a country check means.

The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.

01

Is BPC-157 legal in every European country?

No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.

02

Is retatrutide available as an approved medicine?

The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.

03

Does a tirzepatide record prove local availability?

No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.

Why the split matters

A matching name is only the first record.

  1. 01

    Resolve identity

    Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.

  2. 02

    Resolve destination

    Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.

  3. 03

    Resolve the exact offer

    Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.

Continue the evidence trail
Search the complete peptide database ↗Compare all five world regions ↗Open all country, province, state, region, and city guides ↗